Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 4Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 4Cardiotoxicity 3Heart Failure 2Cardiomyopathies 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Carvedilol × Breast × Clear all
NCT04023110 2025-10-09

CCTGuide Pilot

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
68 enrolled 20 charts
Breast

Breast Neoplasms, Heart Failure, Cardiomyopathies, Cardiotoxicity

NCT02177175 2022-07-12

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
82 enrolled 13 charts
Breast

Breast Neoplasms

NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT01724450 2018-02-05

Ceccy

University of Sao Paulo

Phase 3 Completed
200 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡